Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

121 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033.
Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D. Tran JQ, et al. Among authors: cadavid d. Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18. doi: 10.1212/NXI.0000000000000018. eCollection 2014 Aug. Neurol Neuroimmunol Neuroinflamm. 2014. PMID: 25340070 Free PMC article.
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.
Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S; RENEW Study Investigators. Cadavid D, et al. Lancet Neurol. 2017 Mar;16(3):189-199. doi: 10.1016/S1474-4422(16)30377-5. Epub 2017 Feb 15. Lancet Neurol. 2017. PMID: 28229892 Clinical Trial.
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.
Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, Whalley ET, Davis JA, Versage EM, Richert JR, Axtell RC, Steinman L, Medori R. Bushnell SE, et al. Among authors: cadavid d. Neurology. 2012 Aug 7;79(6):531-7. doi: 10.1212/WNL.0b013e318259e123. Epub 2012 May 9. Neurology. 2012. PMID: 22573631 Free PMC article.
121 results